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Epstein Barr Virus (EBV) may cause lymphoproliferative disorder that can cause malignancies in patients who are immunosuppressed. These malignancies may be suppressed or
reversed by antiviral therapy including spironolactone.
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We present a case of a 66-year-old female who had been immunosuppressed through use
of interferon and tumor necrosis factor (TNF)-active agents for multiple sclerosis (MS). She
met the criteria for idiopathic CD4 T-lymphocytopenia or non-human immunodeficiency
syndrome (HIV) acquired immunodeficiency syndrome (AIDS). She developed a reactivation
of EBV due to the immunosuppression which caused a subset of Non-Hodgkin’s lymphoma.
The patient was initially treated with valacyclovir but she developed brain lesions of lymphoma and was therefore switched to ganciclovir, after which the EBV viral load decreased. A
year later her brain lesions relapsed. Therefore, she was placed on spironolactone in addition
to ganciclovir, which successfully controlled the virus and prevented further relapse.
This case demonstrates spironolactone’s ability to suppress EBV replication and assist with
prophylaxes against EBV in high-risk patients undergoing solid organ transplant or immunosuppressed patients, hence limiting complications.
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Background

Epstein Barr Virus (EBV) infections are believed to play a major role in the development
of lymphoproliferative disorders that occur
after solid organ transplant. Post-transplant
lymphoproliferative disorders (PTLD) include
all clinical syndromes ranging from infectious
mononucleosis to malignancies that contain
chromosomal abnormalities.1 Due to the advancement of treatments for autoimmune
diseases, such as tumor necrosis factor (TNF)
alpha inhibitors, PTLD can also be seen in
patients being treated for autoimmune conditions. Immunosuppression makes patients
susceptible to viral infections such as EBV even
if they have not received a transplant. EBV cells
would normally be destroyed by EBV cytotox-

ic T cells, but in immune suppressed patients
rates of proliferation of EBV will exceed the
rate of clearance by the immune system, which
will lead to accumulations of mutations.2
Spironolactone has been shown to inhibit EBV
Sm protein which is essential for virus production, expression of viral capsid antigen synthesis and capsid formation.3 Spironolactone has
also demonstrated the ability to inhibit EBV
synthesis in ways not previously targeted with
traditional antiviral medications.

Case Presentation

A 66-year-old white female with a past medical
history of multiple sclerosis (MS), systemic lupus erythematosus (SLE) and breast infection
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was referred to an infectious disease specialist for mycobacterium avium complex (MAC)
lymphadenitis.
The patient visited the infectious disease office
for weakness and myopathy following a breast
abscess drainage. Drainage cultures showed 3+
acid fast bacilli (AFB) compatible with AFBMAC. Her lab results showed extremely low
lymphocyte numbers and a positive EBV test
result. HIV and human T cell leukemia virus
tests were negative. In addition to MAC treatment, the patient was placed on valacyclovir. At
follow-up, lab results suggested EBV reactivation and CD4 count of 51 confirming the diagnosis of non-HIV AIDS.
A few months later, she was admitted to the
hospital for rectal bleeding and altered mental
status. A computed tomography (CT) of the
brain showed irregular enhancements of the
brain with moderate vasogenic edema, smaller
enhancing lesions of the left temporal lobe and
left parietal lobe, and edema with mass effect.
A CT of the abdomen and pelvis showed mild
soft tissue nodularity in the greater omentum,
suggesting peritoneal carcinomatosis with
an unknown primary origin. Omental nodule
biopsy results showed an atypical lymphoid
population. Neoplastic cells were variably sized
and included large cells, histiocytes and occasional plasma cells with geographic necrosis
present. These biopsy findings were consistent
with EBV positive lymphoproliferative disorder
(B cell lymphoma from the EBV infection). A
magnetic resonance imaging (MRI) of the brain
showed multiple lesions that were concerning
for tumor spread.
Due to the brain lesions, the patient was
switched from valacyclovir to ganciclovir,
resulting in her EBV polymerase chain reaction (PCR) viral load dropping from 45,000
to 6,000. A CT of the chest demonstrated
improvement in the extensive bilateral parenchymal changes, bilateral pulmonary opacities
and bilateral pleural effusions. A biopsy demonstrated no malignancy in lung tissue.
The patient was later admitted after 4–5 days
of confusion which had been progressively
worsening. A lumbar puncture was performed,
which showed negative PCR for EBV, protein
of 172 mg/dl, glucose of 41 mg/dl, negative
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VDRL and negative culture. During admission,
an MRI of the brain with and without contrast
demonstrated focal deep and subcortical white
matter hyper-intensity in the right frontal lobe,
with several small nodular foci of enhancement,
as well as nodular intraparenchymal focus of
enhancement in the left occipital lobe. These
MRI results were most consistent with a relapse of EBV. Therefore, the patient was placed
on spironolactone in addition to ganciclovir for
EBV treatment.
A repeat MRI months later demonstrated
resolution of nodular enhancement in the right
frontal lobe shown on a recent comparison
study. The resolution of nodular enhancement
confirmed that ganciclovir in combination with
spironolactone was effective at suppressing
EBV.

Discussion

Cases of PTLD represent a diverse spectrum of
disease states that can vary in terms of clinical
presentations. Disease can be nodal, extra-nodal, localized or disseminated.2 The gastrointestinal tract is a common site for extra-nodal
disease, and the central nervous system can
also be affected in patients with PTLD. PTLD
can resemble self-limited infection or can be
indistinguishable from NHL. In the case presented here, a question exists as to whether
the PTLD was caused by the post-transplant
state or the medications used to treat of autoimmune disease.
The diagnosis and classification of PTLD are
currently based on histologic criteria. In the
immunocompetent host, EBV infections can
be detected with antiviral capsid antigen IgM
and IgG antibodies and anti-EBV antigen antibodies.1 Pathologic examination of tissue is
currently the gold standard for PTLD diagnosis.
Ann Arbor Staging classification with Cotswold’s modification is used to stage NHL and
is recommended for staging of PTLD. Diagnostic challenges can include the availability of
techniques to detect oncogene arrangements
and mutations which may not be available in all
centers.
Angioimmunoblastic T-cell lymphoma (AITL) is
a subset of NHL. Patients typically present in
the sixth or seventh decade of life. There is no
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gender predilection for AITL. The clinical syndrome is characterized by generalized lymphadenopathy, hepatosplenomegaly, anemia and
hypergammaglobulinemia. Many infectious
diseases and agents have been reported to be
associated with AITL including tuberculosis,
cryptococcus, EBV, Human Herpes Virus-6, Human Herpes Virus-8, HIV and Hepatitis C virus.
AITL typically presents with systemic illness
such as B symptoms, generalized lymphadenopathy, hepatosplenomegaly and pruritus.
A characteristic feature of AITL is the presence
of an increased number of EBV infected cells.
Immunosuppression, whether from post-transplant medications or immunosuppressive drugs
for autoimmune diseases, leads to reduced
cytotoxic T cells and favors an increase in EBV
infected cells. This causes mutations which can
lead to the development of cancers such as diffuse B cell lymphomas, Burkitts lymphoma and
AITL. Differential diagnosis for AITL includes
the following: reactive hyperplasia, Hodgkin
lymphoma, histiocyte large B cell lymphoma
and peripheral T cell lymphoma.

Therapeutic Intervention

Preventative intervention for PTLD includes
reducing immunosuppression therapy.1 Pharmacologic interventions can be used when
reducing immunosuppression fails. Pharmacologic interventions include B cell monoclonal
antibody therapy in patients with presence of
CD20 on PTLD tissue. B cell monoclonal antibody therapy has shown complete remission in
62.5% of patients in prospective multicenter
trials.1 Antiviral medications include acyclovir,
ganciclovir and, more recently, spironolactone.
Surgical interventions appear to be useful for
treatment of isolated PTLD lesions with tumor
debulking and management of local complications such as gastrointestinal hemorrhage or
perforation.1 Local radiotherapy may be useful
for lesions that occur in the CNS. Interferon
alpha has both antiviral and anti-proliferative
activity and has the advantage of affecting the
host immune response via T-helper cell type
response. Rituximab therapy may be appropriate for treatment of PTLD and its low toxicity and high specificity for CD20 makes it an
attractive option.
The optimal strategy for PTLD relies on prevention. Several studies suggest using antiviral

agents with activity against EBV and cytomegalovirus (CMV), since CMV is a co-factor
in PTLD development. Antiviral drugs with
activity against both EBV and CMV such as
ganciclovir are preferred over acyclovir.2 EBV
can also have mutations in thymidine kinase,
which would favor the use of ganciclovir. Studies that have examined the impact of antiviral
prophylaxis in adults with EBV seronegative
kidney transplants showed that EBV-related
neoplasia incidence was significantly lower in
patients who were treated with valacyclovir or
ganciclovir versus patients who did not receive
CMV prophylaxis.4
Spironolactone has been shown to inhibit the
EBV Sm protein’s function3, which plays an
important role in enhancing the expression of
late lytic cycle EBV genes. Spironolactone has
also been shown to inhibit infectious EBV production and inhibit viral capsid antigen synthesis through Sm production inhibition. This is an
important discovery, which demonstrates new
mechanisms to inhibit EBV infections not previously targeted with traditional medications,
such as ganciclovir and acyclovir. Spironolactone may be used for prophylaxes against EBV
in high-risk patients undergoing solid organ
transplant or patients on immunosuppressive
medications for autoimmune conditions.
Publications regarding the outcome and clinical management of AITL are limited due to the
rare nature of this disease. Patients will usually
die from infectious complications due to immunodeficiency. Numerous treatment options
have been reported such as CHOP therapy
(cyclophosphamide, hydroxydaunomycin, oncovorin, prednisone), CVP (cyclophosphamide,
vincristine, prednisolone) and VAP (vincristine,
asparaginase, prednisone). Remission rate is
approximately 50% but relapse rates remain
high. Other regimens include cyclosporine A,
which has direct cytotoxic effect on lymphocytes, and thalidomide, which has been used
following relapse or refractory AITL, with
promising results.5

Conclusion

Treating EBV can limit the complications of
EBV infection in immunocompromised patients. Spironolactone has the ability to treat
EBV in ways not achieved by other antiviral
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medications. More studies are needed to assess the safety and efficacy of spironolactone’s
activity against EBV. Spironolactone may have
the ability to prevent the reactivation of EBV
and other herpes viruses in high-risk patients
following transplants or immunosuppressive
treatments.
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